Directa Plus – “first commercial contract in Latin America”, again ramptastic?
By Steve Moore | Friday 28 October 2022
Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.
Describing itself as “a leading producer and supplier of graphene nanoplatelets based products for use in consumer and industrial markets”, Directa Plus (DCTA) emphasises a “first commercial contract in Latin America” and the shares have currently responded up to 89.5p.
You must be a registered member to read this story
ShareProphets is reader-supported journalism
Join us for free and gain access to three articles per month
Or become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.